



Novel antioxidant and anti-inflammatory peptides from the Siamese crocodile (Crocodylus siamensis) hemoglobin hydrolysate

Article

Accepted Version

Lueangsakulthai, J., Phosri, S., Theansungnoen, T., Jangpromma, N., Temsiripong, T., McKendrick, J. E., Khunkitti, W. and Klaynongsruang, S. (2017) Novel antioxidant and anti-inflammatory peptides from the Siamese crocodile (*Crocodylus siamensis*) hemoglobin hydrolysate. *Biotechnology and Applied Biochemistry*, 65 (3). pp. 455-466. ISSN 0885-4513 doi: <https://doi.org/10.1002/bab.1628>
Available at <http://centaur.reading.ac.uk/74497/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Published version at: <http://dx.doi.org/10.1002/bab.1628>

To link to this article DOI: <http://dx.doi.org/10.1002/bab.1628>

Publisher: Wiley

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in

the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

1 **Novel antioxidant and anti-inflammatory peptides from the Siamese crocodile**
2 **(*Crocodylus siamensis*) hemoglobin hydrolysate**

3
4 Jiraporn Lueangsakulthai^{1,2}, Santi Phosri^{1,4}, Tinnakorn Theansungnoen^{1,2}, Nisachon Jangpromma^{1,3}, Theeranan
5 Temsiripong⁵, John E. Mckendrick⁶, Watcharee Khunkitti⁷ and Sompong Klaynongsruang^{1,2*}

6
7 ¹ *Protein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI)*

8 ² *Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand*

9 ³ *Office of the Dean, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand*

10 ⁴ *Office of Education, Faculty of Engineering, Burapha University, Chonburi, 20131, Thailand*

11 ⁵ *Srirachamoda Co., Ltd. 383 Moo 4, Nongkham, Sriracha, Chonburi, 20230, Thailand*

12 ⁶ *Department of chemistry, The University of Reading, Reading, RG6 6UR, United Kingdom*

13 ⁷ *Department of Pharmaceutical Technology, Faculty of Pharmaceutical Science, Khon Kaen University, Khon*
14 *Kaen, 40002, Thailand*

15
16 **Address for correspondence: Prof. Sompong Klaynongsruang, Department of Biochemistry, Faculty of*
17 *Science, Khon Kaen University, Khon Kaen, 40002, Thailand. Tel.: +66 43342911; Fax: +66 43342911; e-*
18 *mail: somkly@kku.ac.th.*

19
20 **Running title:** Bioactive peptides from *C. siamensis* hydrolysates

21
22
23
24
25
26
27
28
29
30

31 **Abstract** Novel antioxidant and anti-inflammatory peptides were isolated from hydrolysates of Siamese
32 crocodile (*Crocodylus siamensis*) hemoglobin. *Crocodylus siamensis* hemoglobin hydrolysates (CHHs) were
33 obtained by pepsin digestion at different incubation times (2, 4, 6 and 8 H) at 37 °C and subjected to antioxidant
34 and anti-inflammatory activity assessment. CHH obtained by 2-H hydrolysis (2H-CHH) showed the highest
35 anti-inflammatory activity with respect to decreasing nitric oxide (NO) production, while the strongest
36 antioxidant activity was found for 6-H hydrolysis (6H-CHH) against nitric oxide radicals. To evaluate the anti-
37 inflammatory and antioxidant activity of individual peptide components, 2H-CHH and 6H-CHH were purified
38 by semi-preparative HPLC. Peptide fraction P57 isolated from 6H-CHH was found to exhibit the highest nitric
39 oxide radical inhibition activity (32.0%). Moreover, purification of 2H-CHH yielded peptide fraction P16,
40 which displayed a high efficacy in decreasing NO production of macrophage RAW 264.7 cells (83.2%) and
41 significantly reduced pro-inflammatory cytokines and inflammatory mediators interleukin-6 (IL-6), interleukin-
42 1 beta (IL-1 β) and prostaglandin-E2 (PGE₂) production to about 2.0, 0.3 and 1.9 ng/mL, respectively. Using
43 LTQ orbitrap XL mass spectrometry, active peptide sequences were identified as antioxidant KIYFPHF (KF7),
44 anti-inflammatory SAFNPHEKQ (SQ9) and IIHNEKVQAHGKKVL (IL15). Additionally, CHHs simulated
45 gastric and intestinal *in vitro* digestion positively contributed to antioxidant and anti-inflammatory activity.
46 Taken collectively, the results of this work demonstrate that CHHs contain several peptides with anti-
47 inflammatory and antioxidant properties which may prove valuable as treatment or supplement against diseases
48 associated with inflammation and oxidative stress.

49

50 **Keywords:** *Crocodylus siamensis*, enzymatic hydrolysis, hemoglobin hydrolysate, inflammation, oxidative stress,
51 purification and identification

52

53 **Abbreviations:** CHHs, *Crocodylus siamensis* hemoglobin hydrolysates; cHb, *C. siamensis* hemoglobin; COX-2,
54 cyclooxygenase-2; DH, degree of hydrolysis; IL-1 β , Interleukin 1 beta; IL-6, Interleukin 6; NO, Nitric oxide;
55 PGE₂, Prostaglandin E2; TNF- α , Tumor necrosis factor alpha.

56

57

58

59

60

61 **1. Introduction**

62 Inflammation, oxidative stress and free radical damage have recently been acknowledged as a global threat for
63 human health. Albeit being common by-products of a broad range of processes ensuring cellular homeostasis,
64 excessive generation of radical metabolites is unambiguously associated with a variety of serious disorders such
65 as cancer, heart disease, strokes, Alzheimer's, and premature aging [1]. Similarly, the inflammatory response
66 constitutes an important natural reaction of the host defense system to injury and the invasion of toxins or
67 infectious particles. In the case of pathogenic infection, inflammation contributes to combatting the disease and
68 protecting vital parts of the body, while suspending the normal immune response and shunting certain metabolic
69 pathways at the same time. Specific pro-inflammatory mediators and cytokines, such as NO, PGE₂, TNF- α , IL-
70 1 β and IL-6, comprise vital parts of the inflammatory cascade and are generated to affect immune cell function
71 as well as proliferation activity [2]. In the long term, however, inflammatory processes are known to result in
72 progressive damage and are usually associated with excessive free radical release and oxidative stress [3].

73 The latter is defined as an inequality between the free radicals production and reactive metabolites resulting
74 in damage to cells and important biomolecules which severely impacts all organisms [4]. Free radicals, which
75 account for the majority of both reactive nitrogen species (RNS) and reactive oxygen species (ROS), are defined
76 as molecular species possessing one or more non-bonding paired electrons in spatially different orbitals of atoms
77 or molecules [5]. Also, they have high potential to either donate an electron to or accept an electron from other
78 molecules, consequently behaving as oxidants [6]. The latter process is capable of inflicting severe damage to
79 the membranes and nuclei of cells by oxidizing important biochemical molecules such as proteins, lipids,
80 carbohydrates, and DNA [7]. During the course of the inflammation high amounts of free radicals are produced
81 within the inflamed tissue, in particular NO, which acts as a major pro-inflammatory mediator in the human
82 body and is generated from macrophage in response to the inflammation [8]. In this context NO is generally
83 regarded as the key mediator correlating inflammation and oxidative stress. The discovery and development of
84 substances capable of inhibiting either the activity or production of NO has therefore gained considerable
85 attention within the recent years as they may be utilized to reduce the detrimental effects of both inflammation
86 and oxidative damage.

87 *Crocodylus siamensis*, commonly called Siamese crocodile, is a small freshwater crocodylian populating
88 parts of Southeast Asia, including Thailand. Recently, several components of *C. siamensis* blood, i.e. plasma,
89 serum, white blood cells and hemoglobin have been reported to possess a broad spectrum of biological
90 properties, mainly attributed to abundance of a number of biologically active peptides and proteins. Among

91 these, hemoglobin constitutes the most abundant component and has been shown to exhibit antimicrobial [9],
92 antioxidant [10, 11] and anti-inflammatory activity [11, 12].

93 In addition to the direct extraction of specific proteins with desired biological activity, enzymatic hydrolysis
94 of protein sources has been established as a convenient method to generate novel protein fragments with
95 enhanced biological properties. A variety of animal proteins was shown to be applicable for producing bioactive
96 peptides via protein hydrolysis within recent decades, granting access with specific properties of interest such as
97 inhibitory activity on angiotensin I converting enzyme [13-16], antibacterial activity [17], antioxidant activity
98 [18, 19] and anti-inflammatory activity [20]. In this context, it is anticipated that the biological properties of *C.*
99 *siamensis* blood proteins and their potent antioxidant and anti-inflammatory activity may be further enhanced by
100 protein hydrolysis.

101 As a consequence, this study aimed to investigate the antioxidant and anti-inflammatory peptides from *C.*
102 *siamensis* hemoglobin hydrolysates (CHHs) derived by pepsin digestion. NO scavenging, linoleic peroxidation
103 and ferric reducing power assays were conducted to determine the antioxidant activity of the CHHs, whereas
104 MTT, NO (of macrophage RAW 264.7 cells), IL-6, IL-1 β and PGE₂ assays were used to investigate the anti-
105 inflammatory activity. *In vitro* digestion and hemolytic activity were used to determine the application uses.
106 Furthermore, the identity of the antioxidant and anti-inflammatory peptides was elucidated via amino acid
107 sequence determination using ultra-high performance liquid chromatography-LTQ orbitrap XL mass
108 spectrometry.

109

110 **2. Materials and Methods**

111 **2.1. Materials and reagents**

112 RPMI 1640 medium, antibiotic/antimycotic (penicillin/streptomycin/amphotericin B), trypsin-EDTA and fetal
113 bovine serum (FBS) were purchased from Gibco (USA). Pepsin from porcine gastric mucosa, picrylsulfonic
114 acid solution (TNBS), sodium sulfite, L-leucine, ammonium thiocyanate, ferrous chloride, potassium
115 hexacyanoferrate, ferric chloride, Linoleic acid, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carbonic acid
116 (Trolox), glutathione (GSH), 2,20-azobis-(2-amidinopropane)-dihydrochloride (ABAP), dimethyl sulfoxide
117 (DMSO), lipopolysaccharide (LPS), NaCl, HCl, PBS, bile salts solution, pancreatin solution, CaCl₂, Triton X-
118 100 were purchased from Sigma-Aldrich (Germany). Sodium nitroprusside was purchased from Merck
119 (Germany). 3-(4,5-diamethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Eugene
120 (USA).

121 **2.2. Crocodile hemoglobin preparation**

122 Crocodile blood was collected from a slaughterhouse (Srirachamoda Co., Ltd.) in Thailand, and the extraction of
123 hemoglobin from red blood cells was performed following the method of Srihongthong et al. [9]. Blood was
124 collected and transferred to 15 mL sterile tubes containing 0.08 g of EDTA. Blood samples were stored at 4 °C
125 overnight to allow blood cells to settle. Red blood cells (bottom layer) were collected in sterile tubes after
126 elimination of plasma (top layer) and white blood cells (middle layer). Isolated red blood cells were washed
127 three times with phosphate buffer saline (PBS), pH 7.0, and centrifuged at 3,000g for 5 min at 4 °C. Ice-cold
128 distilled water of five-fold volume was added to the RBC pellet, followed by vigorous mixing and allowing the
129 mixture to settle for 10 min. After centrifugation at 10,000g for 20 min at 4 °C, the supernatant was collected for
130 lyophilization and then stored at -70 °C.

131

132 **2.3. Enzymatic hydrolysis**

133 Enzymatic hydrolysis was performed according to the method of Yu et al. [21]. Shortly, the hemoglobin
134 solution was digested by pepsin with a ratio of enzyme to substrate of 1:100 (w/w) at 37 °C for 2, 4, 6 and 8 H
135 and boiled at 95 °C for 10 min to quench the reaction by inactivating the enzyme. The hydrolysis condition of
136 hemoglobin by pepsin was performed at pH 2.0 (adjusted with 1 M HCl), followed by removal of insoluble
137 components by centrifugation at 7,168g for 20 min. The supernatant was collected and adjusted to pH 7.0 by
138 addition of 1 M HCl or 1 M NaOH. Finally, the supernatants of the crocodile hemoglobin hydrolysates (CHHs)
139 were lyophilized and stored at -20 °C.

140

141 **2.4. Degree of hydrolysis**

142 The degree of hydrolysis was determined following the method of Benjakul et al. [22]. Briefly, 125 µL of CHHs
143 were added to 2.0 mL of 0.21 M sodium phosphate buffer, pH 8.2, followed by addition of 1 mL of 0.01%
144 TNBS solution. The mixture was incubated in a water bath at 50 °C for 30 min in the dark, and 2 mL of 0.1 M
145 sodium sulfite was added to stop the reaction. The mixture was then allowed to cool for 15 min. The absorbance
146 was measured at 420 nm and the α -amino acid content expressed in terms of L-leucine. The percentage of the
147 degree hydrolysis was calculated using the formula:

$$148 \text{ DH} = [(L_t - L_0)/(L_{\text{max}} - L_0)] \times 100$$

149 where L_0 determines the amount of α -amino acid expressed in the sample. L_t corresponds to the amount of α -
150 amino acid released at time t . L_{max} determines the maximum amount of α -amino acid after hydrolysis by 5 M
151 HCl at 100 °C for 24 H.

152

153 **2.5. Nitric oxide (NO) scavenging assay**

154 Nitric oxide (NO) was generated from sodium nitroprusside and measured using Griess reagent. The assay was
155 conducted according to the method of Yen et al. [23] with modifications. For the experiment, 250 μ L sodium
156 nitroprusside (10 mM) in PBS were mixed with 15, 31, 62, 125, 250 and 500 μ g/mL of CHHs and incubated at
157 25 °C for 2 H. An aliquot of the incubated solution (100 μ L) was added to 100 μ L of Griess reagent (1%
158 sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride) and incubated in the
159 dark for 10 min before measuring the absorbance at 540 nm. Butylated hydroxytoluene (BHT) was used as a
160 positive control. All samples were analyzed in quadruplicate. The percentage of inhibition was calculated using
161 the formula: % inhibition = $[(Abs_{cont} - Abs_{test})/Abs_{cont}] \times 100$.

162

163 **2.6. Linoleic peroxidation assay**

164 This assay was performed following the method of Ledesma et al. [24] with modifications. Briefly, 50 μ L of
165 CHHs (0.005, 0.05, 0.5, 5, 50 and 500 μ g/mL) were added to 50 μ L of linoleic acid (0.05% v/v) solution. 0.07
166 M ABAP (10 μ L) was added and the solution mixed for 10 min. After addition of 150 μ L 20% (v/v) acetic acid,
167 the mixture was incubated at 70 °C for 1 H. Twenty microliter of each solution was then added to a 96-well
168 plate already containing 75% ethanol (160 μ L), 15% ammonium thiocyanate (10 μ L) and 10 mM ferrous
169 chloride (10 μ L). The new solution was mixed and incubated at for 3 min. The absorbance was measured at 500
170 nm and Trolox used as positive control. All samples were analyzed in sextuplicate. The antioxidant activity was
171 analyzed and the percentage of antioxidant inhibition (% AI) of each sample was calculated using the following
172 formula:

$$173 \text{ \% AI (antioxidant inhibition) } = 100 \times [Abs_{cont} - Abs_{test})/Abs_{cont}]$$

174

175 **2.7. Ferric reducing power assay**

176 This assay was modified from the method of Girgih et al. [25]. Briefly, 250 μ L of CHHs (0.005, 0.05, 0.5, 5, 50
177 and 500 μ g/mL) and positive control (glutathione) were added to 250 μ L of 0.2 M phosphate buffer, pH 6.6. 250
178 μ L of 1% (w/v) potassium hexacyanoferrate solution were added, vortexed and the mixture incubated at 50 °C

179 for 20 min. The reaction was quenched by adding 250 μ L of 10% TCA and incubated for 10 min before
180 centrifugation at 800g for 10 min. Aliquots of each solution (30 μ L) were then transferred to a 96-well plate
181 already containing double distilled water (160 μ L) and 0.1% (w/v) ferric chloride (10 μ L). The reaction mixture
182 was homogenized and incubated at 25 °C for 10 min, followed by measuring the absorbance at 700 nm. All
183 samples were analyzed in quadruplicate. The antioxidant activity for each sample was expressed as Trolox
184 (mM) equivalents and calculated using the equation of the standard curve of the positive control.

185

186 **2.8. Cell culture**

187 A murine macrophage cell line (RAW 264.7) was purchased from the American Type Culture Collection
188 (American Type Culture Collection [ATCC], USA) and cultured in RPMI 1640 medium supplemented with
189 10% heat-inactivated fetal bovine serum (FBS), 100 μ g/mL of streptomycin, 100 U/mL of penicillin, 25 μ g/mL
190 amphotericin B and incubated at 37 °C in a 5% CO₂ humidified atmosphere.

191

192 **2.9. Measurement of nitric oxide**

193 This assay was conducted according to the method of Phosri et al. [11]. CHHs (62, 125, 250 and 500 μ g/mL)
194 were mixed with LPS (100 ng/mL), and the resulting solution incubated with RAW 264.7 cells. Another
195 incubation was set up between LPS and RAW 264.7 cells at 37 °C in a 5% CO₂ humidified atmosphere for 24
196 H. 100 μ L of culture medium from each CHH sample were slightly mixed with 100 μ L of Griess reagent and
197 incubated at 25 °C for 10 min. The absorbance was measured at 540 nm using a microplate reader (BioRad,
198 Model 680, USA). Nitric oxide (NO) production was calculated as percentage of control. All samples were
199 analyzed in quadruplicate.

200

201 **2.10. Cell viability**

202 Cell viability determination was performed using the MTT assay according to the method of Phosri et al. [11].
203 RAW 264.7 cells (1×10^5 cells/mL) were cultured on a 96-well plate overnight. Lipopolysaccharides (LPS)
204 were co-incubated with CHHs in defined concentrations (62, 125, 250 and 500 μ g/mL) and 100 ng/mL of LPS
205 at 37 °C in a 5% CO₂ humidified atmosphere. After incubation for 24 H the medium was discarded. MTT (3-
206 (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (0.5 mg/mL) was added to RAW 264.7 cells and
207 incubated at 37 °C in a 5% CO₂ humidified atmosphere for 30 min before the medium was discarded. DMSO
208 was added and the reaction mixture incubated at 25 °C for 30 min. The absorbance was measured at 570 nm and

209 the cell viability evaluated by comparing the absorbance with that of the control for each sample. All samples
210 were analyzed in quadruplicate.

211

212 **2.11. Measurement of IL-6, IL-1 β and PGE₂**

213 Aliquots of culture medium employed in the NO assay were further used for determination of IL-6, IL-1 β and
214 PGE₂ expression using the ELISA kit and following the instructions in the manufacturer's manual (R&D,
215 Minneapolis, MN, USA).

216

217 **2.12. Peptide purification from crocodile hemoglobin hydrolysates**

218 The purification of CHH was performed according to the method of Srihongthong et al. [9] with modifications.
219 A HPLC system connected to a C-18 reverse phase column (10 \times 150 mm; SunfireTM prep 5 μ m) was employed
220 in the purification process. Fractions were separated using a mobile phase system consisting of mobile phase A
221 (0.1% TFA in deionized water) and mobile phase B (60% acetonitrile in 0.1% TFA) with a flow rate of 1.0 mL/
222 min. A gradient of 0-25% (v/v) B over 15 min, then 25-100% (v/v) B over 95 min was applied. The elution
223 peaks were collected by monitoring the absorption at 220 nm. The antioxidant and anti-inflammatory activity of
224 all peaks were assayed, followed by determination of the amino acid sequences for each peak showing
225 significant biological activity.

226

227 **2.13. Amino acid sequence analysis**

228 The active fractions P16 of 2H-CHH and P57 of 6H-CHH were selected and the peptides identified using LTQ
229 orbitrap XL Mass spectrometry employing the following search parameters: non-specified enzymatic cleavage
230 with three possible missed cleavages, \pm 0.8 Da mass tolerances for MS and MS/MS, a peptide mass tolerance
231 of \pm 5 ppm, methionine oxidation and Gln->pyro-Glu (N-term Q) variable modification, and monoisotopic
232 mass. Data were additionally processed at the Mascot Server (<http://www.matrixscience.com/>) using MS/MS
233 ion searches against SwissProt (current release).

234

235 **2.14. *In vitro* simulated gastric and intestinal digestion**

236 *In vitro* digestion models were used to simulate the condition of human stomach and intestine for observing
237 remaining activity of CHHs as described by Cheong et al. [26] with modification. The ratio of sample: simulated
238 gastric: simulated intestinal was 1: 1.5: 2. Simulated gastric solution was prepared by dissolving 2 g of NaCl, 7

239 mL of HCl and 3.2 g pepsin with DI up to 1 L. The pH was adjusted to 1.6 using 1 M HCl and maintained at 37
240 °C in a temperature-controlled water bath (Julabo, Germany). Each CHHs were mixed and pH was adjusted to
241 2.5 using 1 M HCl then incubated at 37 °C for 1 H. The simulated intestinal solution was prepared by mixing
242 160 mL bile salts solution (5 mg/mL in PBS), 100 mL of pancreatin solution (4.8 mg/mL in PBS) and 40 mL of
243 CaCl₂ solution (110 mg/mL in PBS). The pH was adjusted to 7 and maintained at 37 °C in a temperature-
244 controlled water bath. After the gastric digestion, samples were immediately adjusted to pH 7 with 1 M NaOH.
245 Digested samples were added to simulated intestinal solution and incubated at 37 °C for 2 H. Samples were
246 adjusted to pH 9 to ensure enzyme inactivation.

247

248 **2.15. Hemolytic activity**

249 The hemolytic activity was determined according to the method of Pata et al. [27]. After isolation of the
250 erythrocytes by centrifugation at 1,000g for 5 min, human red blood cells (hRBCs) were washed three times
251 with PBS, pH 7.4 and then adjusted to 2% (v/v). Ten microliter CHHs were added separately to the 100 µL
252 reaction solution, incubated for 1 H at 37 °C and centrifuged at 1,000g for 5 min. 100 µL of supernatant was
253 then transferred into 96-well plate. The absorbance was measured at 415 nm. 1% (v/v) Triton X-100 and DI
254 used as positive and negative control respectively. All samples were analyzed in quadruplicate.

255

256 **2.16. Statistical analysis**

257 Statistical analysis was performed using ANOVA and followed by Dunnett's test (Prism 5.0, GraphPad Inc., San
258 Diego, CA, USA). Data are presented as mean ± SEM. A value of $P < 0.05$ was accepted to be significant ($*P <$
259 0.05 , $**P < 0.01$, $***P < 0.001$).

260

261 **3. Results and Discussion**

262 **3.1. Preparation of crocodile hemoglobin hydrolysates (CHHs) and degree of hydrolysis (DH)**

263 In the present study, crocodile (*C. siamensis*) hemoglobin was extracted from red blood cells. To obtain active
264 fragments, crocodile hemoglobin was hydrolyzed by pepsin digestion at different reaction times. The extent of
265 enzymatic protein degradation was evaluated by degree of hydrolysis (DH) which was 20.4%, 23.1%, 25.0%
266 and 35.9% for 2 H, 4 H, 6 H and 8 H of incubation, respectively (Fig. 1). Results indicated that cleavage of
267 peptide bonds was higher in longer enzymatic hydrolysis.

268

269 3.2. Antioxidant activity, purification and amino acid sequence identification of CHHs

270 NO is a very unstable radical which produces highly reactive molecules [28]. Intact crocodile Hb and all
271 investigated Hb hydrolysates inhibited NO radicals (Fig. 2a). Notably, the hydrolysates had superior antioxidant
272 activity compared to intact Hb at all concentrations (15-500 $\mu\text{g}/\text{mL}$). The NO-scavenging activity of the intact
273 protein (500 $\mu\text{g}/\text{mL}$) was 75.7%, while the inhibitory ability of the hydrolysates, including 2H-CHH, 4H-CHH,
274 6H-CHH and 8H-CHH, showed inhibition percentages of 77.4%, 78.2%, 88.3% and 83.1%, respectively.
275 Moreover, BHT employed as positive standard displayed 77.8% NO radical inhibition. These results indicate
276 that CHHs obtained by pepsin digestion possess pronounced antioxidant activity against nitric oxide radicals.
277 From the report of Kabbua et al. [29] found that recombinant α -globin from cHb can act as a heme-nitric oxide
278 and/or oxygen binding (H-NOX) hemoprotein. Furthermore, the value of NO inhibition activity of CHH was
279 higher than yellowfin tuna hydrolysate [30].

280 Lipid peroxidation is considered to be a free radical process involving a source of secondary free radical, which
281 can act as secondary messenger or directly react with other biomolecules, enhancing biochemical lesions. The
282 results of linoleic peroxidation assay reveal that 2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH (at concentrations
283 of 0.005-500 $\mu\text{g}/\text{mL}$) effected significant inhibition of linoleic peroxidation in a concentration dependent
284 manner when compared with Trolox. The inhibitory ability of all hydrolysates, including 2H-CHH, 4H-CHH,
285 6H-CHH and 8H-CHH were 94.2%, 79.0%, 97.0% and 82.2%, respectively. Moreover, Trolox (500 $\mu\text{g}/\text{mL}$)
286 showed 94.4% of linoleic peroxidation inhibition and intact Hb showed 89.1% inhibition (Fig. 2b). Furthermore,
287 the linoleic peroxidation inhibition of protein hydrolysates obtained from smooth hound has been investigated.
288 As shown by the results, the value of this activity was lower than that obtained in this study [31].

289 2H-CHH, 4H-CHh, 6H-CHH and 8H-CHH at the highest concentration (500 $\mu\text{g}/\text{mL}$) displayed significant ferric
290 ion reducing power. 4H-CHH displayed the highest reduction activity equivalent to Trolox of about 2.1 mM,
291 while intact Hb, 2H-CHH, 6H-CHH and 8H-CHH displayed reduction equivalents of 0.8, 1.2, 1.4 and 0.6 mM
292 Trolox (Fig. 2c). Moreover, 500 $\mu\text{g}/\text{mL}$ glutathione (positive control) affected significant ferric ion reduction
293 equivalent to Trolox at 18.60 mM (data not shown). It has been reported that hydrolysates with high reducing
294 power show a great ability to donate electrons to form stable compounds and thereby interrupt the free radical
295 chain reactions and showing antioxidant activity [32].

296 Due to displaying the highest antioxidant activity in prior experiments, 6H-CHH was subjected to purification
297 by reverse phase C-18 column semi-preparative HPLC to identify the contained active peptide components. As
298 shown in Fig. 3a, 61 individual fractions were eluted. All elution peaks were normalized to a concentration of 78

299 $\mu\text{g/mL}$ and screened with respect to antioxidant activity by nitric oxide scavenging assay. After the activity
300 screening, several active fragments including P2, P39, P40, P43, P45, P46 and P57 were associated with nitric
301 oxide radical inhibition rates of 19.5%, 21.2%, 17.3%, 16.1%, 18.7%, 18.1% and 32.0%, respectively. The
302 highest activity in inhibiting nitric oxide radicals was found for P57 (32.0%), while the positive control (BHT)
303 showed 68.1% nitric oxide radical inhibition (Fig. 3b).

304 The primary structures of the purified antioxidant peptides were elucidated using LTQ orbitrap XL mass
305 spectrometry (Fig. 4). Amino acid sequence of P57 was KIYFPHF (KF7) with molecular mass of 476.26 Da. As
306 shown in Table 1, antioxidant peptide KF7 showed 42% hydrophobicity and a +1 net charge. Alignment of the
307 amino acid sequences of the peptide fragments with cHb indicated the antioxidant peptides originated from the
308 α -subunit, this observation is in excellent agreement with results of Srihongthong et al. [9], who reported that
309 the α -subunit of cHb exhibited higher antioxidant activity than the β -subunit. Peptide fractions from acid-
310 digested cHb with a molecular mass of 180 to 3,000 Da are reported to exhibit antioxidant activity [33].
311 Notably, mass spectrometric analysis further revealed an apparent correlation of peptide length with biological
312 activity as antioxidant peptides were found to be smaller and shorter molecules. In a previous study, Peña-
313 Ramos et al. [34] reported that the presence of particular amino acids including His, Tyr, Met, Lys, Trp and Pro
314 correlates with increased antioxidant potency of most food-derived peptides. Likewise, the presence of Leu, Ile,
315 His, Met, Tyr, Lys and Trp is assumed to contribute to the reducing power of protein hydrolysates [35]. In
316 addition, peptides containing His residues have been documented to exhibit protective effects against lipid
317 peroxidation. An imidazole ring of His has been implicated in the donation of hydrogen and trapping of lipid
318 radicals [36]. Trp, Tyr and Met exhibited the highest antioxidant properties, followed by Phe, Cys and His [37].
319 Nitric oxide, however, is also scavenged by CHH, presumably due to the presence of reactive thiol groups [38].

320

321 3.3. Anti-inflammatory activity, purification and amino acid sequences identification of CHHs

322 The anti-inflammatory property of intact Hb and CHHs was evaluated on the basis of NO production and cell
323 viability against macrophage RAW 264.7 cells (Fig. 5). After induction of inflammation in RAW 264.7 cells by
324 LPS for 24 H, the percentage of nitric oxide production was defined as 100% when treated with LPS. Fig. 5a,
325 2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH (at concentrations of 62-500 $\mu\text{g/mL}$) show nitric oxide production
326 decrease in a concentration dependent manner. Intact Hb, 2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH at a
327 concentration of 500 $\mu\text{g/mL}$ show nitric oxide production at 56.5%, 52.6%, 68.6%, 62.0% and 60.9%,
328 respectively. In order to evaluate potential cytotoxic effects of CHHs, the viability of RAW 264.7 cells treated

329 with defined concentrations of CHHs was determined (Fig. 5b). The results showed that intact Hb, 2H-CHH,
330 4H-CHH, 6H-CHH and 8H-CHH at concentrations of 62-500 $\mu\text{g/mL}$ had no observable effect on cell viability
331 while the viability percentage of cells treated with LPS only was defined as 100%. This result indicates that
332 CHHs show high efficacy to reduce nitric oxide production and are essentially non-toxic to macrophage RAW
333 264.7 cells, these results correlate with that from the report of Phosri et al. [11] who reported that cHb provides
334 anti-inflammatory activity via the suppression of nitric oxide synthase (NOS), which inhibits the NO
335 production. Jangpromma et al. [39] reported that cHb significantly decreased the production of NO in LPS-
336 stimulated RAW 264.7 cells and decreased inducible nitric oxide synthase (iNOS). In addition, results showed
337 that CHHs have higher anti-inflammatory activity than gastropod (*Harpa ventricosa*) hydrolysate [40].
338 Since 2H-CHH was found to possess the highest anti-inflammatory activity, its peptide constituents were
339 purified by reverse phase C-18 column semi-preparative HPLC. The resulting chromatogram depicted in Fig. 6a
340 consists of 59 fraction peaks which were diluted to a concentration of 31 $\mu\text{g/mL}$ prior to anti-inflammatory
341 activity determination. The assay revealed 6 peaks (P16, P17, P28, P29, P30 and P38) which show nitric oxide
342 production at 83.2%, 86.0%, 87.9%, 88.8%, 86.3% and 83.6% (Fig. 6b) with no effect on the viability of RAW
343 264.7 cells (Fig. 6c). Moreover, these fractions were also selected to determine the influence on the expression
344 levels of IL-6, IL-1 β and PGE₂ (Table 2). The results indicate that P16, P17, P28, P29, P30 and P38 are able to
345 significantly decrease IL-6 and PGE₂ production, whereas P16 and P17 further inhibited IL-1 β production.
346 Notably, P16 showed the highest activity to decrease IL-6 levels (approximately 2.0 ng/mL) compared to LPS
347 and effectively decreased the IL-1 β level to about 0.3 ng/mL. P16 showed the highest activity to reduce PGE₂
348 levels (approximately 1.9 ng/mL) when compared to LPS. Furthermore, P16 was found to reduce the production
349 of pro-inflammatory cytokines and inflammatory mediators IL-6, IL-1 β and PGE₂, which are associated with the
350 inflammation-related in neuropathological diseases, for example Alzheimer's, multiple sclerosis and cerebral
351 ischemia [41, 42]. IL-6 that acts as a multifunctional cytokine was up-regulated by lipopolysaccharide (LPS). In
352 inflammation, trauma and autoimmune diseases were found high expression levels of IL-1 β and IL-6 [43].
353 Furthermore, IL-1 β induced IL-6 production is mediated predominantly through the p38 MAPK/NF- κ B
354 pathway [44]. cHb was found to exhibit anti-inflammatory effects in the cotton pellet model and RAW 264.7
355 cells by reducing expression levels of IL-1 β , TNF- α , COX-2 and IL-6 mRNA [39, 45]. The collected results in
356 this work indicate that the anti-inflammatory activity of sample might be related to an interaction with the
357 MAPK/NF- κ B pathway by their ability to decrease pro-inflammatory cytokine and inflammatory mediator
358 production.

359 The primary structures of the purified anti-inflammatory peptides were elucidated using LTQ orbitrap XL mass
360 spectrometry (Fig. 4). Amino acid sequences of P16 were determined as SAFNPHEKQ (SQ9) and
361 IHNKVKVAHGKKVL (IL15) corresponding to molecular mass of 529.26 Da and 857.51 Da, respectively. As
362 shown in Table 1, anti-inflammatory peptides SQ9 and IL15 had hydrophobicity values of about 22% and 40%,
363 together with net charges of 0 and +2, respectively. The sequence of the anti-inflammatory peptide showed
364 strong correlation with the β -chain of cHb. Likewise, the anti-inflammatory activity of SQ9 and IL15 was traced
365 back to the presence of specific amino acids. According to reports, anti-inflammatory peptides can be found in a
366 wide molecular weight range [20, 46]. Hydrophobic amino acid side chains (e.g. Leu, Phe, Val, Ile, and Trp) as
367 well as positively charged amino acids (Lys, Arg and His) were documented to have a major influence on the
368 anti-inflammatory activity of peptides [47-52].

369

370 3.4. *In vitro* simulated gastric and intestinal digestion of CHHs and its activity

371 Simulated gastric and intestinal digestion (*in vitro* digestion model) was used as the conditions of human
372 stomach and intestine. The degree of hydrolysis of 2H-CHH and 6H-CHH after intestinal digestion was
373 increased about 3.7% and 8.8%, respectively. From the results, it is inferred that CHH tended to be more
374 hydrolyzed by intestinal digestion. Gastrointestinal tract is known to be a major oxidation site where various
375 free radicals are generated in the digestion process [53]. As shown in Fig. 7a, 6H-CHH after intestinal digestion
376 was inhibited nitric oxide (42.5%, the concentration of 125 $\mu\text{g}/\text{mL}$) and exhibited higher reducing power (2.8
377 mM Trolox equivalent, the concentration of 500 $\mu\text{g}/\text{mL}$) than 6H-CHH before intestinal digestion (Fig. 7b).
378 With excellent agreement with Moure et al. [36] who reported that the reducing power increased with higher
379 degree of hydrolysis. The anti-inflammatory activity of 2H-CHH after intestinal digestion showed NO
380 production (19.8%, the concentration of 125 $\mu\text{g}/\text{mL}$) without toxicity against macrophage RAW 264.7 cells
381 (Figs. 8a and 8b). During the course of the inflammation high amounts of free radicals are produced within the
382 inflamed tissue, in particular NO, which acts as a major pro-inflammatory mediator in the human body and is
383 generated from macrophage in response to the inflammation [8]. In this context, NO is generally regarded as the
384 key mediator correlating inflammation and oxidative stress. The capability of NO production has decreased
385 resulting in the reduction of detrimental effects of both inflammation and oxidative damage. The hemolytic
386 activity was performed to determine the toxicity against human red blood cells and the results showed that both
387 2H-CHH and 6H-CHH at all concentrations were not toxic against human red blood cells (Figs. 9a and 9b). So
388 far, only a few bioactive peptides including peptides in this study displaying activities *in vitro* that have been

389 proven effective *in vivo*. Results indicated that both 2H-CHH and 6H-CHH with intestinal digestion have
390 potential to be used as an alternative source of antioxidant and anti-inflammatory agents with safety.

391

392 **4. Conclusions**

393 A number of novel antioxidant and anti-inflammatory peptides were derived from pepsin hydrolysis of cHb.
394 Experimental evidence collected in this study indicates the antioxidant fragment is a comparatively small
395 peptide, consisting of only 7 amino acid residues with slightly positive charge and low hydrophobicity.
396 Similarly, the peptides with anti-inflammatory activity were found to comprise 9 and 15 amino acid residues,
397 respectively, and are also characterized by positive charge and low hydrophobicity. This is the first report to
398 identify antioxidant and anti-inflammatory peptides from pepsin digested cHb. Due to their remarkable
399 biological activity, ease of production and absence of cytotoxicity, these naturally-derived peptides are believed
400 to bear a great potential for a future application as health promoting supplements and therapeutic agents against
401 inflammation and oxidative stress-related conditions.

402

403 **5. Acknowledgements**

404 This research was financial supported by the Royal Golden Jubilee Ph.D. program (RGJ-PHD program), Grant
405 No. [PhD 0258/2552]. We also grateful to the Protein and Proteomics Research Center for Commercial and
406 Industrial Purposes (ProCCI), Department of Biochemistry, Faculty of Science, Khon Kaen University,
407 Department of Pharmaceutical Technology, Faculty of Pharmaceutical Science, Khon Kaen University and
408 Department of chemistry, The University of Reading, United Kingdom for essential support by laboratory
409 facilities. Additionally, we would like to thank Srirachamoda Co., Ltd., Chon Buri, Thailand for supplying
410 crocodile blood samples. The authors declare no conflict of interest.

411

412 **6. References**

- 413 [1] Pham-huy, L. A., He, H., and Pham-huy, C. (2008) *Int. J. Biomed. Sci.* 4, 89-96.
414 [2] Kim, J. Y., Kim, T. H., and Kim, S. S. (2008) *Biochem. Bioph. Res. Co.* 368, 779-785.
415 [3] Reuter, S., Gupta, S. C., Chaturvedi, M. M., and Aggarwal, B. B. (2010) *Free. Radic. Biol. Med.* 49,
416 1603-1616.
417 [4] Duracková, Z. (2010) *Physio. Res.* 59, 10.
418 [5] Bagchi, K., and Puri, S. (1998) *East. Mediterranean. Health. Jr.* 4, 350-360.

- 419 [6] Cheeseman, K. H., and Slater, T. F. (1993) *Br. Med. Bull.* 49, 481-493.
- 420 [7] Young, I. S., and Woodside, J. V. (2001) *Clin. Pathol.* 54, 176-186.
- 421 [8] Guslandi, M. (1998) *Eur. J. Clin. Invest.* 28, 904-907.
- 422 [9] Srihongthong, S., Pakdeesuwan, A., Daduang, S., Araki, T., Dhiravisit, A., and Thammasirirak, S. (2012)
- 423 *Protein J.* 31, 466-476.
- 424 [10] Jandaruang, J., Siritapetawee, J., Thumanu, K., Songsiriritthigul, C., Krittanai, C., Daduang, S.,
- 425 Dhiravisit, A., and Thammasirirak, S. (2012) *Protein J.* 31, 43-50.
- 426 [11] Phosri, S., Mahakunakorn, P., Lueangsakulthai, J., Jangpromma, N., Swatsitang, P., Daduang, S.,
- 427 Dhiravisit, A., and Thammasirirak, S. (2014) *Protein J.* 33, 484-492.
- 428 [12] Kommanee, J., Phosri, S., Daduang, S., Temsiripong, Y., Dhiravisit, A., and Thammasirirak, S. (2014)
- 429 *Chiang. Mai. J. Sci.* 41, 627-634.
- 430 [13] Maruyama, S., Nakagomi, K., Tomozuka, N., and Suzuki, H. (1985) *Agric. Biol. Chem.* 49, 1405-1409.
- 431 [14] Balti, R., Arroume, N. N., Yaba, E. A., Guillochon, D., and Nasri, M. (2010) *J. Agric. Food. Chem.* 58,
- 432 3840-3846.
- 433 [15] Balti, R., Arroume, N. N., Bougatef, A., Guillochon, D., and Nasri, M. (2010) *Food. Res. Int.* 43, 1136-
- 434 1143.
- 435 [16] Aissaoui, N., Abidi, F., Hardouin, J., Abdelkafi, Z., Marrakchi, N., Jouenne, T., and Marzouki, M. N.
- 436 (2016) *Biotechnol. Appl. Biochem.* 64, 201-210.
- 437 [17] Zucht, H. D., Raida, M., Adermann, K., Mägert, H. J., and Forssmann, W.G. (1995) *FEBS Lett.* 372,
- 438 185-188.
- 439 [18] Carlsen, C. U., Rasmussen, K. T., Kjeldsen, K. K., Westergaard, P., and Skibsted, L. H. (2003) *Eur.*
- 440 *Food. Res. Technol.* 217, 195-200.
- 441 [19] Chang, C., Wu, K., and Chiang, S. (2007) *Food Chem.* 100, 1537-1543.
- 442 [20] Ahn, C., Cho, Y., and Je, J. (2015) *Food Chem.* 168, 151-156.
- 443 [21] Yu, Y., Hu, J., Miyaguchi, Y., Bai, X., Du, Y., and Lin, B. (2006) *Peptides.* 27, 2950-2956.
- 444 [22] Benjakul, S., and Morrissey, M. (1997) *J. Agric. Food. Chem.* 45, 3423-3430.
- 445 [23] Yen, G. C., Lai, H.H., and Chou, H.Y. (2001) *Food Chem.* 74, 471-478.
- 446 [24] Ledesma, B. H., Hsieh, C. C., and Delumen, B. O. (2009) *Biochem. Biophys. Res. Commun.* 390, 803-
- 447 808.
- 448 [25] Girgih, A. T., Udenigwe, C. C., and Aluko, R.E. (2011) *J. Am. Oil. Chem. Soc.* 88, 381-389.

- 449 [26] Cheong, A. M., Tan, C. P., and Nyam, L. (2016) *Ind. Crops. Prod.* 87, 1-8.
- 450 [27] Pata, S., Yaraksa, N., Daduang, S., Temsiripong, Y., Svasti, J., Araki, T., and Thammasirirak, S. (2011)
- 451 *Dev. Comp. Immunol.* 35, 545-553.
- 452 [28] Patra, J. K., Lee, S. W., Park, J. G., and Baek, K. H. (2017) *J. Food. Biochem.* 41, e12278.
- 453 [29] Kabbua, T., Anwised, P., Boonmee, A., Subedi, B. P., Pierce, S. B. and Thammasirirak, S. (2014) *Protein*
- 454 *Expr. Puri.* 103, 56-63.
- 455 [30] Han, Y., Byun, S. H., Park, J. H., and Kim, S. B. (2015) *Int. J. Food Sci. Tech.* 50, 1996-2003.
- 456 [31] Bougatef, A., Hajji, M., Balti, R., Lassoued, I., Triki-ellouz, Y., and Nasri, M. (2009) *Food Chem.* 114,
- 457 1198-1205.
- 458 [32] Xie, Z. J., Huang, J. R., Xu, X. M., and Jin, Z. Y. (2008) *Food Chem.* 111, 370-376.
- 459 [33] Pakdeesuwan, A., Araki, T., Daduang, S., Payoungkiattikun, W., Jangpromma, N., and Klaynongsruang,
- 460 S. (2017) *J. Microbiol. Biotechnol.* 27, 26-35.
- 461 [34] Peña-Ramos, E. A, Xiong, Y. L., and Arteaga, G. E. (2004) *J. Sci. Food. Agric.* 84, 1908-1918.
- 462 [35] Qian, Z., Jung, W., Byun, H., and Kim, S. (2008) *Bioresource Technol.* 99, 3365-3371.
- 463 [36] Moure, A., Dominguez, H., and Parajo, J. C. (2006) *Process Biochem.* 41, 447-456.
- 464 [37] Dávalos, A., Miguel, M., Bartolome, B., and López-Fandiño, R. (2004) *J. Food. Protect.* 67, 1939-1944.
- 465 [38] Vitturi, D. A., Sun, C. W., Harper, V. M., Williams, B. T., Medellin, N. C., Chacko, B. K., Peng, N., Dai,
- 466 Y., Wyss, M., Townes, T., and Patel, R. P. (2013) *Free. Radical. Bio. Med.* 55, 119-129.
- 467 [39] Jangpromma, N., Poolperm, N., Pornsri, K., Anwised, P., Kabbua ,T., Phosri, S., Daduang, S., and
- 468 Klaynongsruang, S. (2017) *Chiang Mai J Sci* 44, 1-16.
- 469 [40] Joshi, I., Sudhakar, S., and Nazeer, R. B. (2016) *Appl. Biochem. Biotechnol.* 180, 1128-1140.
- 470 [41] Tomimoto, H., Akiguchi, I., Wakita, H., Lin, J. X., and Budka, H. (2000) *Acta Neuropathol.* 99, 26-30.
- 471 [42] Muzio, L., Martino, G., and Furlan, R. (2007) *Neuroimmunol.* 191, 39-44.
- 472 [43] Yoon, H. J., Moon, M. E., Park, H., Im, S. Y., and Kim, Y. H. (2007) *Biochem. Biophys. Res. Commun.*
- 473 358, 954-959.
- 474 [44] Liu, X., Ye, F., Xiong, H., Ninghu, D., Limb, G. A., Xie, T., Peng, L., Zhang, P., Wei, Y., Zhang, W.,
- 475 Wang, J., Wu, H., Lee, P., Song, E., and Zhang, D. Y. (2015) *Exp. Cell. Res.* 331, 223-231.
- 476 [45] Phosri, S., Jangpromma, N., Patramanon, R., Kongyingyoes, B., Mahakunakorn, P., and
- 477 Klaynongsruang, S. (2017). *Inflammation* 40, 205-220.

- 478 [46] Mukhopadhyaya, A., Noronha, N., Bahar, B., Ryan, M. T., Murray, B. A., Kelly, P. M., O'Loughlin, I. B.,
479 O'Doherty, J. V., and Sweeney, T. (2014). *Food. Sci. Nutr.* 2, 712-723.
- 480 [47] Vogel, H. J., Schibli, D. J., Jing, W., Lohmeier-vogel, E. K., Epand, R. F., and Epand, R. M. (2002)
481 *Biochem. Cell. Biol.* 80, 49-63.
- 482 [48] Nan, Y. H., Park, K. H., Jeon, Y. J., Park, Y. K., Park, I. S., Hahm, K. S., and Shin, S. Y. (2007) *Protein.*
483 *Peptide. Lett.* 14, 1003-1007.
- 484 [49] Kovacs-Nolan, J., Zhang, H., Ibuki, M., Nakamori, T., Yoshiura, K., and Turner, P. V. (2012) *Biochim.*
485 *Biophys. Acta.* 1820, 1753-1763.
- 486 [50] Chatterton, D.E., Nguyen, D. N., Bering, S. B., and Sangild, P. T. (2013) *Int. J. Biochem. Cell. Biol.* 45,
487 1730-1747.
- 488 [51] Majumder, K., Chakrabarti, S., Davidge, S. T., and Wu, J. (2013) *J. Agric. Food. Chem.* 61, 2120-2129.
- 489 [52] Kwak, S. J., Kim, C. S., Choi M. S., Park, T., Sung, M. K., Yun, J. W., Yoo, H., Mine, Y., and Yu, R.
490 (2016) *J. Med. Food.* 19, 678-685.
- 491 [53] Chen, M., and Li, B. (2012) *Innov. Food. Sci. Emerg. Technol.* 16, 341-348.
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499
- 500
- 501
- 502
- 503
- 504
- 505
- 506
- 507

TABLE 1 *Structural characteristics of the anti-inflammatory peptides (P16) from 2H-CHH and antioxidant peptide (P57) from 6H-CHH*

<i>Properties</i>	<i>Peptide sequences</i>	<i>Hydrolysates</i>	<i>% hydrophobicity</i>	<i>Net charge</i>	<i>Sequence alignment</i>
Anti-inflammatory	SAFNPHEKQ (SQ9)	2H-CHH	22%	0	cHb β -subunit (position 2-10)
Anti-inflammatory	IIHNEKVQAHGKKVL (IL15)	2H-CHH	40%	+2	cHb β -subunit (position 55-69)
Antioxidant	KIYFPHF (KF7)	6H-CHH	42%	+1	cHb α -subunit (position 41-47)

508

509

510

511

512

TABLE 2

IL-6, IL-1 β and PGE₂ production in LPS-stimulated RAW 264.7 cells incubated with purified fractions of 2H-CHH at a concentration of 31 μ g/mL

<i>Fraction peaks (P)</i>	<i>The production concentration (ng/mL)</i>		
	<i>IL-6</i>	<i>IL-1β</i>	<i>PGE₂</i>
LPS	10.647 \pm 0.213	0.360 \pm 0.002	6.486 \pm 0.163
P16	2.019*** \pm 0.000	0.315*** \pm 0.002	1.871*** \pm 0.068
P17	7.287*** \pm 0.447	0.338 \pm 0.001	1.877*** \pm 0.042
P28	7.967*** \pm 0.110	0.420*** \pm 0.002	3.046*** \pm 0.220
P29	9.340* \pm 0.155	0.412*** \pm 0.001	3.578*** \pm 0.035
P30	9.407* \pm 0.116	0.430*** \pm 0.002	2.880*** \pm 0.205
P38	4.707*** \pm 0.173	0.538*** \pm 0.011	3.181*** \pm 0.377

521

*denotes $P < 0.05$ and *** denotes $P < 0.001$. Data expressed as a mean \pm SEM of 3 independent experiments.

Significance was measured using ANOVA followed by Dunnett's test.

524

525

526

527

528

529 **Figure captions**

530

531 **FIG. 1** *Degree of hydrolysis (% DH) of CHH after pepsin digestion for 2, 4, 6 and 8 H. Hemoglobin*
 532 *hydrolyzed enzymatically by pepsin displayed a direct correlation between the rate of hydrolysis (DH)*
 533 *and the time of incubation (H).*

534

535 **FIG. 2** *(a) Nitric oxide scavenging activity of CHHs at concentrations of 15-500 µg/mL. Each bar displays the*
 536 *mean ± SEM of four demonstrations. (** P < 0.01 and *** P < 0.001) probability levels compared*
 537 *with BHT. (b) Linoleic peroxidation activity of CHHs at concentration of 0.005-500 µg/mL. Each bar*
 538 *displays the mean ± SEM of six demonstrations. (* P < 0.05, ** P < 0.01 and *** P < 0.001)*
 539 *probability levels compared with Trolox and (c) reducing power of CHHs at concentration of 0.005-*
 540 *500 µg/mL expressed in Trolox equivalents. Each bar displays the mean ± SEM of four demonstrations.*
 541 *(***P < 0.001) probability levels compared with glutathione.*

542

543 **FIG. 3** *Reverse phase C-18 column semi-preparative HPLC profile of (a) 6H-CHH. 0.1% Trifluoroacetic acid*
 544 *(TFA) in deionized water and 60% acetonitrile in 0.1% Trifluoroacetic acid (TFA) were chosen as*
 545 *mobile phase A and B, respectively. CHH was filtered through 25 mm PES filters and 700 µg (4 mL)*
 546 *were injected at 1.0 mL/min of flow rate. The linear gradient was 0-25% (v/v) mobile phase B over 15*
 547 *min, then 25-100% (v/v) mobile phase B over 95 min. (b) The antioxidant activity of purified peaks*
 548 *from 6H-CHH (78 µg/mL) determined by the nitric oxide scavenging assay. Each bar displays the*
 549 *mean ± SEM of four demonstrations (***) P < 0.001).*

550

551 **FIG. 4** *Mass spectrogram of anti-inflammatory peptides and antioxidant peptide from P16 (2H-CHH) and P57*
 552 *(6H-CHH), respectively, determined by LTQ orbitrap XL mass spectrometry. The following sequence*
 553 *interpretation was concluded: anti-inflammatory peptides were identified as (a) Ser-Ala-Phe-Asn-Pro-*
 554 *His-Glu-Lys-Gln (SAFNPHEKQ) and (b) Ile-Ile-His-Asn-Glu-Lys-Val-Gln-Ala-His-Gly-Lys-Lys-Val-*
 555 *Leu (IIHNEKVQAHGKKVL) and (c) the antioxidant peptide was identified as Lys-Ile-Tyr-Phe-Pro-*
 556 *His-Phe (KIYFPHF).*

557

558 **FIG. 5** *The effect of CHHs on (a) NO production in LPS-activated macrophage RAW 264.7 cells and (b) the*
559 *cytotoxicity (cell viability) of CHHs on macrophage RAW 264.7 cells determined by the MTT assay.*
560 *CHHs (62-500 µg/mL) were then incubated with macrophage RAW 264.7 cells and another overnight*
561 *incubation was set between LPS and macrophage RAW 264.7 cells. The media were further used to*
562 *measure the nitrite level (NO assay). Each bar displays the mean ± SEM of four demonstrations (* P <*
563 *0.05, ** P < 0.01 and *** P < 0.001).*

564
565 **FIG. 6** *Reverse phase C-18 column semi-preparative HPLC profile of (a) 2H-CHH. 0.1% Trifluoroacetic acid*
566 *(TFA) in deionized water and 60% acetonitrile in 0.1% Trifluoroacetic acid (TFA) were chosen as*
567 *mobile phase A and B, respectively. CHH was filtered through 25 mm PES filters and 700 µg (4 mL)*
568 *were injected at 1.0 mL/min of flow rate. The linear gradient was 0-25% (v/v) mobile phase B over 15*
569 *min, then 25-100% (v/v) mobile phase B over 95 min. (b) The anti-inflammatory property of purified*
570 *peaks from 2H-CHH (31 µg/mL) against NO production determined in LPS-activated macrophage*
571 *RAW 264.7 cells. (c) The cytotoxicity (cell viability) of purified peaks from 2H-CHH (31 µg/mL) on*
572 *macrophage RAW 264.7 cells determined by the MTT assay. Each bar displays the mean ± SEM of four*
573 *demonstrations (* P < 0.05, ** P < 0.01 and *** P < 0.001).*

574
575 **FIG. 7** *(a) Nitric oxide scavenging activity of 6H-CHHs after intestinal digestion at concentrations of 15-125*
576 *µg/mL. Each bar displays the mean ± SEM of four demonstrations. (* P < 0.05 and *** P < 0.001)*
577 *probability levels compared with BHT. (b) Reducing power at concentration of 0.005-500 µg/mL*
578 *expressed in Trolox equivalents. Each bar displays the mean ± SEM of four demonstrations. (***)*
579 *0.001) probability levels compared with glutathione.*

580
581 **FIG. 8** *The effect of 2H-CHHs after intestinal digestion on (a) NO production in LPS-activated macrophage*
582 *RAW 264.7 cells and (b) the cytotoxicity (cell viability) on macrophage RAW 264.7 cells determined by*
583 *the MTT assay. 2H-CHHs (31-125 µg/mL) were then incubated with macrophage RAW 264.7 cells and*
584 *another overnight incubation was set between LPS and macrophage RAW 264.7 cells. The media were*
585 *further used to measure the nitrite level (NO assay). Each bar displays the mean ± SEM of four*
586 *demonstrations (* P < 0.05, ** P < 0.01 and *** P < 0.001).*

587

588 **FIG. 9** *The hemolytic activity of (a) 2H-CHH after intestinal digestion and (b) 6H-CHH after intestinal*
589 *digestion against human red blood cells. Each bar displays the mean \pm SEM of four demonstrations*
590 *(*** $P < 0.001$).*

591

592